-Reuters
Eagle Pharmaceuticals Announces Licensing Agreement With AOP Orphan For US Commercial Rights To Landiolol, A Beta-1 Adrenergic Blocker; Co. To Make $5M Upfront Payment And Potential Milestone Payments
-- Eagle poised to facilitate regulatory pathway for approval in the U.S. based on existing data from Japanese and European studies, with no additional clinical work expected –
-- Anticipates filing new drug
